The psychometric properties of the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) in patients with HBV-related liver disease

Mei LIU¹, Yuanyuan WANG,², Jing ZHAO¹, Sujun ZHENG¹, Gabor S. UNGVARI³, Chee H. NG⁵, Zhong-ping DUAN¹*, Yutao XIANG²*

Background: Comorbid depression in Hepatitis B virus (HBV) is common. Developing accurate and time-efficient tools to measure depressive symptoms in HBV is important for research and clinical practice in China.

Aims: This study tested the psychometric properties of the Chinese version of the 16-item Quick Inventory of Depressive Symptomatology (QIDS-SR) in HBV patients.

Methods: The study recruited 245 depressed patients with HBV and related liver disease. The severity of depressive symptoms was assessed with the Montgomery-Asberg Depression Rating Scale (MADRS) and the QIDS-SR.

Results: Internal consistency (Cronbach’s alpha) was 0.796 for QIDS-SR. The QIDS-SR total score was significantly correlated with the MADRS total score (r=0.698, p<0.001). The QIDS-SR showed unidimensional measurement properties in exploratory factor analysis.

Conclusions: The QIDS-SR (Chinese version) has good psychometric properties in HBV patients and appears to be useful in assessing depression in clinical settings.

Key words: Depressive symptoms, psychometric properties, QIDS-SR, Hepatitis B Virus

[Shanghai Arch Psychiatry. 2017; 29(1): 15-20. doi: http://dx.doi.org/10.11919/j.issn.1002-0829.216076]

1. Introduction

Chronic hepatitis B virus (HBV) infection affects around 300-400 million people worldwide.¹² In China, there are approximately 93 million HBV carriers and about 30 million suffer from chronic hepatitis B.²³ HBV infection is progressive and may lead to cirrhosis, liver failure and hepatocellular carcinoma, causing significant personal suffering and considerable socioeconomic burden.²⁴

In the past decade psychiatric comorbidity in HBV-infection has gained increasing attention. Preliminary evidence indicates that comorbid depression is common in Chinese HBV patients,⁵ which could be mediated by a variety of factors including antiviral medications, disease-related physical symptoms and the socioeconomic consequences of high treatment costs.⁶,⁷ HBV-related diseases are associated with fatigue,
loss of appetite, abdominal pain and psychological disturbances, such as low self-esteem. Furthermore, discrimination and stigma related to HBV disease often affects patients and their families. All these factors could increase the risk of psychiatric comorbidities, particularly depression. As depression is eminently treatable, particularly when detected early, routine depression screening would be important in the medical management of HBV patients.

Numerous studies have examined comorbid depression in HBV. The measures on depression included the Beck Depression Inventory and its short version, the Hospital Anxiety and Depression Scale and the Zung Self-Rating Depression Scale. The 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR) is a widely used, self-report instrument with well-established psychometric properties. The QIDS-SR can reliably assess depressive symptoms in the previous week in a time-efficient manner in physically healthy psychiatric patients. However, its psychometric properties have not been assessed in medically compromised HBV patients.

The current study set out to examine the psychometric properties of the Chinese version of the QIDS-SR in patients with HBV and related liver diseases.

2. Methods
2.1 Settings and subjects
The study was conducted between June 1, 2014 and January 31, 2015 in Beijing YouAn Hospital, which is an 800-bed university affiliated teaching hospital for infectious diseases. Both inpatients and outpatients were consecutively screened to participate. Study entry criteria were as follows: (1) age 18 years or above; (2) diagnosis of HBV carrier, chronic hepatitis B (CHB), hepatitis B cirrhosis or HBV-related Hepatocellular Carcinoma (HCC) according to the Guidelines of Prevention and Treatment for Chronic Hepatitis B (2010 version) and the Recommendations of the Asian Pacific Association for the Study of the Liver (APASL) for the management of hepatocellular carcinoma; (3) a total score of 7 or above on the Montgomery-Asberg Depression Rating Scale (MADRS) indicating at least mild depression; (4) ability to communicate, understand the purpose of the study and tolerate a one-hour interview. The study protocol was approved by the Beijing YouAn Hospital Clinical Research Ethics committee. All patients provided written informed consent.

2.2 Instruments and assessment
The Chinese version of the QIDS-SR was used to measure the severity of depressive symptoms within the past week. A total score was computed by adding scores of its nine symptom domains: (1) low mood; (2) concentration/decision-making; (3) self-outlook; (4) thoughts of death or suicide; (5) involvement; (6) energy level; (7) sleep (the highest score on any one of the four relevant items – sleep onset insomnia, mid nocturnal insomnia, early morning insomnia and hypersomnia); (8) appetite/weight change (the highest score on any one of the four relevant items – weight increase, weight decrease, appetite increase and appetite decrease) and (9) agitation/retardation (the highest score on any one of the two relevant items – psychomotor slowing or psychomotor agitation). The total score ranges between 0 and 27, with higher scores indicating more severe depressive symptoms. The MADRS–Chinese version was used to measure the severity of depressive symptoms within the past week as the reference standard for sensitivity to change of depressive symptoms measured by the QIDS-SR. The MADRS is a generic measure of severity of depressive symptoms and widely used in the general population and with patients with medical conditions. Higher MADRS scores indicate more severe depression.

2.3 Statistical analysis
Data were analyzed with SPSS version 20.0. Cronbach’s alpha was calculated to determine internal consistency. Internal consistency was regarded acceptable if the Cronbach’s alpha was greater than 0.6. The item-scale correlations of the QIDS-SR were tested using Pearson correlation coefficients. Convergent validity was calculated by Pearson correlation between the QIDS-SR and MADRS if the scores on the QIDS-RS and the MADRS were normally distributed, otherwise the Spearman correlation was used. The dimensionality of the QIDS-SR was measured by Principal Component Analysis to obtain the most meaningful original factor structure of the QIDS-SR. The scale was unidimensional in patients with HBV, if the percentage of total variance explained by the first principal component was above 20%.

3. Results
Altogether, 689 patients were screened; 245 met study entry criteria and participated in the study. All of them completed the assessment with the QIDS-SR and the MADRS. Table 1a shows the basic demographic and clinical characteristics of the participants. There was no significant difference in demographic and clinical characteristics among the different HBV groups. Cronbach’s alpha for the QIDS-SR was 0.796, indicating good internal consistency. All domains, if deleted, consistently decreased the total scale alpha (Table 1b). The QIDS-SR was highly correlated with the MADRS (r=0.698, p<0.001), indicating good convergent validity for the QIDS-SR. Principal component analysis was carried out to examine whether the QIDS-SR was unidimensional. The percentage of total variance explained by the first principal component for the QIDS-SR was 27.4%, thus indicating unidimensionality of the QIDS-SR.
Figure 1. Flowchart of study

812 HBV related patients
- 92 patients declined to participate; 31 did not complete;

689 included in analysis
- 62 HBV carrier
  - 42 did not have depressive

- 241 Chronic hepatitis B
  - 173 did not have depressive symptoms

- 198 HBV-related hepatitis B
  - 131 did not have depressive symptoms

- 188 HBV-related HCC
  - 98 did not have depressive

Table 1a. Basic demographic and clinical characteristics of the study sample (n=245)

|                          | whole sample | HBV carrier (n=20) | Chronic hepatitis B (n=68) | HBV-related cirrhosis (n=67) | HBV-related HCC (n=90) |
|--------------------------|--------------|--------------------|---------------------------|----------------------------|------------------------|
|                          | N(%)         | N(%)               | N(%)                      | N(%)                       | N(%)                   |
| Inpatients               | 157(64.1)    | 0(0)               | 0(0)                      | 67(100.0)                  | 90(100)                |
| Male                     | 179(73.1)    | 8(40)              | 40(58.8)                  | 54(80.6)                   | 77(85.6)               |
| Married                  | 205(83.7)    | 14(70)             | 54(79.4)                  | 59(88.1)                   | 78(86.7)               |
| Local residents          | 104(42.4)    | 7(35)              | 23(33.8)                  | 25(37.3)                   | 49(54.4)               |
| Living alone             | 12(4.9)      | 1(5)               | 1(1.5)                    | 7(10.4)                    | 3(3.3)                 |
| Personal income <3000 yuan | 87(35.5) | 6(30)             | 18(26.5)                  | 23(34.3)                   | 40(44.4)               |
| Having health insurance' to 'Health insurance coverage | 4(1.6) | 0(0) | 0(0) | 2(3) | 2(2.2) |
| Family history of psychiatric disorders | 8(3.3) | 0(0) | 5(7.4) | 1(1.5) | 2(2.2) |
| Current alcohol use      | 47(19.2)     | 2(10)              | 18(26.5)                  | 13(19.4)                   | 14(15.6)               |

|                          | Mean(SD)     | Mean(SD)           | Mean(SD)                  | Mean(SD)                  | Mean(SD)               |
| Age (years)              | 48.3(13.7)   | 34.4(10.4)         | 37.2(11.0)                | 51.0(10.6)                | 57.7(9.0)              |
| Education (years)        | 10.8(3.8)    | 11.5(4.3)          | 11.6(3.3)                 | 9.9(4.5)                  | 10.8(3.3)              |
| Age of onset of HBV (years) | 34.1(15.0) | 20.9(8.0)         | 27.0(14.2)                | 37.6(13.9)                | 39.8(13.8)             |
| Duration of HBV-related liver disease (years) | 14.3(11.4) | 13.6(8.9) | 10.3(8.8) | 13.9(12.4) | 17.7(11.9) |
| Number of hospitalizations | 2.6(4.1) | 0.1(0.3)       | 0.4(0.7)                  | 3.2(5.9)                  | 4.3(3.4)               |
| MADRS total              | 14.8(7.3)    | 14.8(10.5)         | 14.3(6.7)                 | 15.7(6.7)                 | 14.5(7.2)              |
| QIDS-SR total            | 8.7(3.9)     | 8.8(4.3)           | 7.6(3.8)                  | 10.2(4.1)                 | 8.5(3.6)               |

1 USD=6 Yuan; HCC=Hepatocellular Carcinoma; MADRS=Montgomery-Asberg Depression Scale; QIDS-SR= Quick Inventory of Depressive Symptomatology–Self-Report; SF-12=Medical Outcomes Study Short Form 12
4. Discussion

4.1 Main findings

To the best of our knowledge, this was the first study that examined the psychometric properties of the QIDS-SR in patients with HBV. The findings indicate that QIDS-SR is a reliable and valid instrument for screening depressive symptoms in HBV patients.

Acceptable internal consistency (>0.65) was found for the QIDS-SR in testing HBV patients, which is consistent with the findings in clinically depressed samples. Item-to-total score correlations showed that the sleep and appetite/weight domains had the lowest correlation, confirming other findings in depression. Moreover, item-to-total score correlations of sad mood and involvement had the highest correlation, which is also consistent with the results found in depression. Compared to the MADRS, the QIDS-SR showed good convergent validity. This is consistent with initial structure obtained in depression where the Hamilton Depression Rating Scale (HAMD) was used as the comparator rating instrument. Principal component analysis identified one major factor from the QIDS-SR, suggesting that the factorial structure of the QIDS-SR in HBV patients is the same as found in depression.

4.2 Limitations

Due to the following limitations, the results of this study need to be viewed with caution. First, only patients in one hospital were included, therefore the findings are not applicable to all areas of China. Second, test-retest reliability was not measured because most depressed patients were treated once they were identified. Finally, useful information, such as use of antidepressants and other medications or comorbid anxiety or other physical complications, were not recorded.

4.3 Implications

In conclusion, the Chinese version of the QIDS-SR is an effective tool with good validity and reliability in a clinical sample. Considering that the QIDS-SR could provide independent information about depressive symptoms in a time-efficient manner, it could be useful in assessing depression in patients with HBV infection.

Funding

This work was supported by the Base to Clinical and Scientific Research Cooperation fund of Capital Medical University (15JL67), the High-tech personnel training grant from Beijing Health System (2015-3-104) and the Beijing municipal education commission on science and technology plan projects (KM201610025021).

Conflict of interest statement

Authors do not have any conflict of interest in conducting this study and preparing the manuscript.

Ethical approval

This study was approved by the Ethics Committee of the Beijing YouAn Hospital (No. 22 (2014)).

Informed consent

All patients provided written informed consent.

Table 1b. Quick Inventory of Depressive Symptomatology (QIDS-SR) scores in HBV patients

| n=245 | Mean(Standard Deviation) | Item-total correlation | p     | Alpha if item deleted |
|-------|--------------------------|------------------------|-------|-----------------------|
| Sleep | 2.1(0.8)                 | 0.27**                 | p<0.001 | 0.79                 |
| Low mood | 1.2(0.7)                 | 0.52**                 | p<0.001 | 0.75                 |
| Appetite / weight | 1.3(0.9)                 | 0.35**                 | p<0.001 | 0.78                 |
| Concentration / Decision making | 0.7(0.6)                 | 0.59**                 | p<0.001 | 0.74                 |
| Self outlook | 0.8(0.8)                 | 0.48**                 | p<0.001 | 0.75                 |
| Thoughts of death or suicide | 0.3(0.6)                 | 0.49**                 | p<0.001 | 0.75                 |
| Involvement | 0.8(0.8)                 | 0.57**                 | p<0.001 | 0.74                 |
| Energy level | 1.0(0.5)                 | 0.47**                 | p<0.001 | 0.76                 |
| Agitation / retardation | 0.6(0.7)                 | 0.52**                 | p<0.001 | 0.75                 |
| Total score | ---                     | ---                    | ---   | ---                   |

*<0.05; **<0.001
抑郁症状快速评定量表自评版（QIDS-SR）应用于 HBV 相关肝脏疾病患者的心理测量学特性

刘梅，王园园，赵景，郑素军，Gabor S. U，Chee H. N，段钟平，项玉涛

背景：乙型肝炎病毒（HBV）感染伴发抑郁症是一种常见的现象。建立精确并且有时效的工具，用以评估 HBV 患者抑郁症状，对研究和临床实践是非常重要的。

目的：这项研究测试了抑郁症状快速评定量表自评版（QIDS-SR）在乙型肝炎患者中使用的心理测量学特性。

方法：这项研究招募了 245 名患有乙型肝炎病毒和相关肝病的抑郁症患者。采用蒙特玛莉抑郁评定量表（MADRS）和 QIDS-SR 评估抑郁症状的严重程度。

结果：QIDS-SR 的内部一致性（(Cronbach α) 为 0.796。其总分与 MADRS 总分显著相关 (r=0.698, p<0.001)。探索性因素分析的 QIDS-SR 显示一维测量性能。

结论：QIDS-SR（中文版）在乙型肝炎患者中有良好的心理测量学特性，并且在评估临床抑郁症方面是有效的。

关键词：抑郁症状，心理测量学特性，QIDS-SR，乙型肝炎病毒

References

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol. 2004; 38(10 Suppl 3): S158-168. doi: http://dx.doi.org/10.1097/00004836-200411003-00008

2. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012; 30(12): 2212-2219. doi: http://dx.doi.org/10.1016/j.vaccine.2011.12.012

3. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine. 2009; 27(47): 6550-6557. doi: http://dx.doi.org/10.1016/j.vaccine.2009.08.048

4. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol. 2005; 34 Suppl 1: S1-S3. doi: http://dx.doi.org/10.1016/j.jcv.2004.12.012

5. Duan Z, Kong Y, Zhang J, Guo H. Psychological comorbidities in Chinese patients with acute-on-chronic liver failure. Gen Hosp Psychiatry. 2012; 34(3): 276-281. doi: http://dx.doi.org/10.1016/j.genhosppsych.2011.11.012

6. Guo HM, Liu M, Xiang YT, Zhao J, Ungvari GS, Correll CU, et al. Insomnia in adults with chronic hepatitis B, liver failure and cirrhosis: A case-control study. Perspect Psychiatr Care. 2015; doi: http://dx.doi.org/10.1111/ppc.12138

7. Irwin M. Neuroimmunology of disordered sleep and depression. Neuropsychopharmacology. 2001; 25(Suppl): S45-49. doi: http://dx.doi.org/10.1016/S0893-133X(01)00338-4

8. Volk RJ, Pace TM, Parchman ML. Screening for depression in primary care patients: Dimensionality of the Short Form of the Beck Depression Inventory. Psychological Assessment. 1993; 5(2): 173. doi: http://dx.doi.org/10.1037/1040-3590.5.2.173

9. Kunkel EJ, Kim JS, Hann H-W, Oyesanmi O, Menefee LA, Field HL, et al. Depression in Korean immigrants with hepatitis B and related liver diseases. Psychosomatics. 2004; 41(6): 472-480. doi: http://dx.doi.org/10.1176/appi.psy.41.6.472

10. Altindag A, Cadirci D, Sirmatel F. Depression and health related quality of life in non-cirrhotic chronic hepatitis B patients and hepatitis B carriers. Neurosciences (Riyadh). 2009; 14(1): 56-59

11. Qureshi MO, Khokhar N, Shafqat F. Severity of depression in hepatitis B and hepatitis C patients. J Coll Physicians Surg Pak. 2012; 22(10): 632-634

12. Özkan M, Çorapçıoğlu A, Balcıoğlu I, Ertekin E, Khan S, Özdemir S, et al. Psychiatric morbidity and its effect on the quality of life of patients with chronic hepatitis B and hepatitis C. Int J Psychiatry Med. 2006; 36(3): 283-297. doi: http://dx.doi.org/10.2190/d37v-x0jy-39mj-pvxq

13. Atesci FC, Cetin BC, Özgünhanoglu NK, Karadag F, Turgut H. Psychiatric disorders and functioning in hepatitis B virus carriers. Psychosomatics. 2005; 46(2): 142-147. doi: http://dx.doi.org/10.1176/appi.psy.46.2.142

14. Koskinas J, Merkouraki P, Manesis E, Hadziyannis S. Assessment of depression in patients with chronic viral hepatitis: effect of interferon treatment. Digestive Diseases. 2003; 20(3-4): 284-288. doi: http://dx.doi.org/10.1159/000067682

15. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4: 561-571. doi: http://dx.doi.org/10.1001/archpsyc.1961.0170120031004

16. Mumford D, Tareen I, Bajwa M, Bhatti M, Karim R. The translation and evaluation of an Urdu version of the Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1991; 83(2): 81-85. doi: http://dx.doi.org/10.1111/j.1600-0447.1991.tb07370.x
17. Zung WW. A self-rating depression scale. Arch General Psychiatry. 1965; 12(1):63-70
18. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003; 54(5):573-583. doi: http://dx.doi.org/10.1016/s0006-3223(02)01866-8
19. Trivedi MH, Rush A, Ibrahim H, Carmody T, Biggs M, Suppes T, et al. The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychological medicine. 2004; 34(01): 73-82. doi: http://dx.doi.org/10.1017/s0033291703001107
20. Fava M, A John Rush M, Alpert JE, Balasubramani G, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry. 2008; doi: http://dx.doi.org/10.1176/appi.ajp.2007.06111868
21. Jia JD, Li L. [The guideline of prevention and treatment for chronic hepatitis B (2010 version)]. Zhong Hua Gan Zang Bing Za Zhi. 2011; 19:13-24. Chinese
22. Sarin SK, Kumar A, Almeida JA, Chawla YK, Fan ST, Garg H, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL). Hepatol Int. 2009; 3(1):269-282. doi: http://dx.doi.org/10.1007/s12072-008-9106-x
23. Liu J, Xiang YT, Wang G, Zhu XZ, Ungvari GS, Kilbourne AM, et al. Psychometric properties of the Chinese versions of the Quick Inventory of Depressive Symptomatology - Clinician Rating (C-QIDS-C) and Self-Report (C-QIDS-SR). J Affect Disord. 2013; 147(1-3): 421-424. doi: http://dx.doi.org/10.1016/j.jad.2012.08.035
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979; 134:382-389. doi: http://dx.doi.org/10.1192/bjp.134.4.382
25. Zhu CM, Zhang MY. Montgomery and Asberg Depression Scale - Chinese version. In: Zhang MY, ed. [Handbook of Rating Scales in Psychiatry]. Changsha, Hunan: Hunan Sciences & Technology Press; 1998. pp: 127-129. Chinese
26. Lako IM, Bruggeman R, Kneegtering H, Wiersma D, Schoevers RA, Slooff CJ, et al. A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. J Affect Disord. 2012; 140(1):38-47. doi: http://dx.doi.org/10.1016/j.jad.2011.10.014
27. Reckase MD. Unifactor Latent Trait Models Applied to Multi-Factor Tests: Results and Implications. J Educ Stat. 1979; 4:207-230. doi: dx.doi.org/10.1037/1164671
28. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, et al. An evaluation of the quick inventory of depressive symptomatology and the hamilton rating scale for depression: a sequenced treatment alternatives to relieve depression trial report. Biol Psychiatry. 2006; 59(6):493-501. doi: http://dx.doi.org/10.1016/j.biopsych.2005.08.022
29. Gutteling JJ, de Man RA, van der Plas SM, Schalm SW, Busschbach JJ, Darlington AS. Determinants of quality of life in chronic liver patients. Aliment Pharmacol Ther. 2006; 23(11): 1629-1635. doi: http://dx.doi.org/10.1111/j.1365-2036.2006.02934.x
30. Kan Q, Wen J, Xue R. Discrimination against people with hepatitis B in China. Lancet (London, England). 2015; 386(9990): 245-246. doi: http://dx.doi.org/10.1016/s0140-6736(15)61276-4
31. Huang J, Guan ML, Balch J, Wu E, Rao H, Lin A, et al. Survey of Hepatitis B Knowledge and Stigma among Chronically Infected Patients and Uninfected Persons in Beijing, China. Liver Int. 2016. doi: http://dx.doi.org/10.1111/liv.13168
32. Mirabolghah Hazaveh M, Dormohammadi Toosi T, Nasiri Toosi M, Tavakoli A, Shahbazi F. Prevalence and severity of depression in chronic viral hepatitis in Iran. Gastroenterol Rep (Oxf). 2015; 3(3): 234-237. doi: http://dx.doi.org/10.1093/gastro/gou091
33. Duan Z, Kong Y, Zhang J, Guo H. Psychological comorbidities in Chinese patients with acute-on-chronic liver failure. Gen Hosp Psychiatry. 2012; 34(3): 276-281. doi: http://dx.doi.org/10.1016/j.genhosppsych.2011.11.012
34. Ma XR, Hou CL, Zang Y, Jia FJ, Lin YQ, Li Y, et al. Could the Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR) be used in depressed schizophrenia patients? J Affect Disord. 2015; 172: 191-194. doi: http://dx.doi.org/10.1016/j.jad.2014.09.051

Dr. Mei Liu graduated from Xi’an Jiaotong University with a doctoral degree in medicine in 2005. She then worked as a physician in the Artificial Liver Center at Beijing Youan Hospital. She went to the University of Texas to further her study as a postdoc from 2013 to 2014. Her research interest is the psychological and somatic changes in patients with liver disease.